Literature DB >> 10827402

Parastomal pyoderma gangrenosum: clinical features and management.

C C Lyon1, A J Smith, M H Beck, G A Wong, C E Griffiths.   

Abstract

BACKGROUND: The importance of pyoderma gangrenosum (PG) as a cause of ulceration around abdominal stomas is not well recognized.
OBJECTIVE: Our purpose was to describe the incidence, clinical and histologic features, disease associations, and possible risk factors for parastomal PG.
METHODS: A clinic, run by a dermatologist and two stoma nurses, was created. Five hundred patients approached by postal questionnaire were invited to attend if they had skin problems. In addition, local surgical, dermatologic, and nursing services were invited to refer patients with parastomal skin problems. Cases of parastomal PG were identified, investigated, and treated.
RESULTS: The annual incidence of parastomal PG in the questionnaire-based cohort of patients was 0.6% (3 patients). An additional 23 patients with the condition were seen. No consistent hematologic, biochemical, immunologic, microbiological or histologic abnormalities were identified. Local skin damage did not appear to be an important trigger for parastomal PG. The condition is recurrent in one third of cases. Topical tacrolimus (0.3% in carmellose sodium paste) has been effective in 4 patients.
CONCLUSION: Parastomal PG is far more common than previous reports would suggest, and it may be associated with diseases other than inflammatory bowel disease.

Entities:  

Mesh:

Year:  2000        PMID: 10827402

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  15 in total

Review 1.  Diagnosis and treatment of pyoderma gangrenosum.

Authors:  Trevor Brooklyn; Giles Dunnill; Chris Probert
Journal:  BMJ       Date:  2006-07-22

Review 2.  The role of tacrolimus in inflammatory bowel disease: a systematic review.

Authors:  Yago Gonzalez-Lama; Javier P Gisbert; Jose Mate
Journal:  Dig Dis Sci       Date:  2006-10       Impact factor: 3.199

3.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

Review 4.  Ostomy Complications in Crohn's Disease.

Authors:  Armen Aboulian
Journal:  Clin Colon Rectal Surg       Date:  2019-06-17

Review 5.  Avoidance and management of stomal complications.

Authors:  Michael Kwiatt; Michitaka Kawata
Journal:  Clin Colon Rectal Surg       Date:  2013-06

Review 6.  Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria.

Authors:  Angelo V Marzano; Rim S Ishak; Simone Saibeni; Carlo Crosti; Pier Luigi Meroni; Massimo Cugno
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

7.  A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum.

Authors:  Ilknur Altunay; Asli Kucukunal; Sezgi Sarikaya; Gulsen Tukenmez Demirci
Journal:  Int Wound J       Date:  2012-10-29       Impact factor: 3.315

8.  Diagnosis and management of parastomal pyoderma gangrenosum.

Authors:  Xian-Rui Wu; Bo Shen
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-04-19

Review 9.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012

10.  Intravenous immunoglobulin use in managing severe, perioperative peristomal pyoderma gangrenosum following subtotal colectomy with end ileostomy for medically refractory chronic ulcerative colitis.

Authors:  Kevin Behm; David W Larson; Dorin Colibaseanu
Journal:  J Surg Case Rep       Date:  2015-03-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.